Identifying mutations in epilepsy genes: Impact on treatment selection

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Recent advances in identifying epilepsy-causing gene mutations and their molecular mechanisms.
• Growing evidence links understanding these mechanisms to personalized treatment selection for epilepsy.

Purpose of the Study:

• To discuss the therapeutic implications of epilepsy-associated gene variants.
• To highlight how genetic etiology guides treatment strategies, including drug selection and avoidance.

Main Methods:

• Review of current literature on genetic epilepsy and therapeutic interventions.
• Analysis of how specific gene mutations (e.g., ion channels, metabolism, signaling pathways) influence treatment response.
• Case examples illustrating genotype-specific treatment approaches and drug repurposing.

Main Results:

• Genetic diagnosis can direct prescription of targeted metabolic treatments (e.g., ketogenic diet, pyridoxine).
• It enables avoidance of detrimental antiepileptic drugs (AEDs) (e.g., sodium channel blockers in SCN1A mutations).
• It facilitates selection of AEDs that counteract mutation effects (e.g., sodium channel blockers for SCN8A mutations) and identifies opportunities for drug repurposing (e.g., memantine for GRIN2A mutations).

Conclusions:

• Understanding the precise genetic cause of epilepsy is crucial for personalized therapy.
• Therapeutic strategies range from correcting metabolic defects to counteracting functional disturbances and repurposing existing drugs.
• Novel treatments targeting specific genetic defects, including small molecules, peptides, antisense oligonucleotides, and gene therapy, are under development.